

# Contents

<b>Preface to the First Edition</b>	<b>ix</b>
<b>Preface to the Second Edition</b>	<b>xi</b>
<b>About the Editors</b>	<b>xiii</b>
<b>Contributors</b>	<b>xv</b>
<b>SECTION I: OVERVIEW OF PHARMACEUTICAL MEDICINE</b>	<b>1</b>
<b>1 The Practice and Practitioners of Pharmaceutical Medicine</b>	<b>3</b>
<i>Anthony W. Fox</i>	
<b>2 Pharmaceutical Medicine as a Medical Specialty</b>	<b>7</b>
<i>Michael D. Young and Peter D. Stonier</i>	
<b>3 Clinical Research Education and Training for Biopharmaceutical Staff</b>	<b>25</b>
<i>Peter Marks</i>	
<b>SECTION II: DRUG DISCOVERY AND DEVELOPMENT</b>	<b>41</b>
<b>Introduction</b>	<b>41</b>
<b>4 Drug Discovery: Design and Serendipity</b>	<b>43</b>
<i>Ronald R. Cobb and Leslie J. Molony</i>	
<b>5 Pharmaceutics</b>	<b>51</b>
<i>Anthony W. Fox</i>	
<b>6 Nonclinical Toxicology</b>	<b>63</b>
<i>Frederick Reno</i>	
<b>7 Informed Consent</b>	<b>75</b>
<i>Anthony W. Fox</i>	
<b>8 Phase I: The First Opportunity for Extrapolation from Animal Data to Human Exposure</b>	<b>79</b>
<i>Stephen H. Curry, Dennis McCarthy, Helen H. DeCory, Matthew Marler and Johan Gabrielsson</i>	
<b>9 Phase II and Phase III Clinical Studies</b>	<b>101</b>
<i>Anthony W. Fox</i>	
<b>10 Phase IV Drug Development: Post-Marketing Studies</b>	<b>119</b>
<i>Lisa R. Johnson-Pratt</i>	

<b>11 Site Management</b>	127
<i>Barry Miskin</i>	
<b>12 Good Clinical Practices</b>	139
<i>Wendy Bohaychuk and Graham Ball</i>	
<b>13 Quality Assurance, Quality Control and Audit</b>	159
<i>Rita Hattemer-Apostel</i>	
<b>14 The Unique Role of Over-the-Counter Medicine</b>	179
<i>Paul Starkey</i>	
<b>SECTION III: SPECIAL POPULATIONS AND REQUIRED SPECIAL STUDIES</b>	<b>191</b>
<b>Introduction</b>	191
<b>15 Drug Research in Older Patients</b>	193
<i>Lionel D. Edwards</i>	
<b>16 Drug Development Research in Women</b>	203
<i>Lionel D. Edwards</i>	
<b>17 Clinical Research in Children</b>	223
<i>Lionel D. Edwards</i>	
<b>18 Racial and Ethnic Issues in Drug Registration</b>	231
<i>Lionel D. Edwards, J.M. Husson, E. Labbé, C. Naito, M. Papaluca Amati, S. Walker, R. Williams and H. Yasurhara</i>	
<b>19 Hepatic and Renal Failure</b>	249
<i>Anthony W. Fox</i>	
<b>20 Drug Interactions</b>	255
<i>Anthony W. Fox and Anne-Ruth van Troostenburg de Bruyn</i>	
<b>21 Orphan Drugs</b>	265
<i>Bert Spilker</i>	
<b>SECTION IV: APPLIED ASPECTS OF DRUG DEVELOPMENT</b>	<b>277</b>
<b>Introduction</b>	277
<b>22 Biotechnology Products and Development</b>	279
<i>David A. Shapiro and Anthony W. Fox</i>	
<b>23 Pharmacoeconomics: Economic and Humanistic Outcomes</b>	291
<i>Raymond J. Townsend, Jane T. Osterhaus and J. Gregory Boyer</i>	
<b>24 Pharmacoepidemiology and the Pharmaceutical Physician</b>	303
<i>Hugh H. Tilson</i>	
<b>25 Statistical Principles and Application in Biopharmaceutical Research</b>	313
<i>Dan Anbar</i>	
<b>26 Data Management</b>	345
<i>T.Y. Lee and Michael Minor</i>	

<b>27 Patient Compliance: Pharmionics, a New Discipline</b>	355
<i>Jean-Michel Métry</i>	
<b>28 Monitoring Drug Concentrations in Clinical Practice</b>	375
<i>Anthony W. Fox</i>	
<b>29 Generics</b>	381
<i>Gabriel Lopez and Thomas Hoxie</i>	
<b>30 Complementary Medicines</b>	387
<i>Anthony W. Fox</i>	
<b>SECTION V: DRUG REGULATION</b>	<b>393</b>
<b>Introduction</b>	393
<b>31 United States Regulations</b>	395
<i>William Kennedy</i>	
<b>32 Special US Regulatory Procedures: Emergency and Compassionate INDs and Accelerated Product Approvals</b>	407
<i>Anthony W. Fox</i>	
<b>33 The Development of Human Medicines Control in Europe from Classical Times to the Year 2000</b>	415
<i>John P. Griffin</i>	
<b>34 Medicines Regulation in the European Union</b>	443
<i>Anne-Ruth van Troostenburg de Bruyn and Giuliana Tabusso</i>	
<b>35 Japanese Regulations</b>	487
<i>Etienne Labbé</i>	
<b>36 Drug Registration and Pricing in the Middle East</b>	509
<i>Edda Freidank-Mueschenborn and Anja König</i>	
<b>SECTION VI: MEDICAL SERVICES</b>	<b>517</b>
<b>Introduction</b>	517
<b>37 Medical Affairs</b>	519
<i>Gregory P. Geba</i>	
<b>38 Drug Labeling</b>	529
<i>Anthony W. Fox</i>	
<b>39 Drug Surveillance</b>	535
<i>Howard J. Dreskin and Win M. Castle</i>	
<b>40 Data Mining</b>	545
<i>Mirza I. Rahman and Omar H. Dabbous</i>	
<b>41 Risk Management in Product Approval and Marketing</b>	557
<i>Anthony W. Fox</i>	

<b>42 Publishing Clinical Studies</b>	565
<i>Anthony W. Fox</i>	
<b>43 Organizing and Planning Local, Regional, National and International Meetings and Conferences</b>	575
<i>Zofia Dziewanowska and Linda Packard</i>	
<b>44 Drug Withdrawals from the Market – Causes and Consequences</b>	579
<i>Ronald D. Mann</i>	
<b>SECTION VII: LEGAL AND ETHICAL ASPECTS OF PHARMACEUTICAL MEDICINE</b>	<b>585</b>
<b>Introduction</b>	585
<b>45 Introduction to Bioethics for Pharmaceutical Professionals</b>	587
<i>Andrew J. Fletcher</i>	
<b>46 Pharmaceutical Medicine and the Law</b>	595
<i>Sarah Croft and Timothy Pratt</i>	
<b>47 Pharmaceutical Product Liability</b>	605
<i>Han W. Choi and Howard B. Yeon</i>	
<b>48 Patents</b>	619
<i>Gabriel Lopez</i>	
<b>49 Fraud and Misconduct in Clinical Research</b>	631
<i>Jane Barrett</i>	
<b>SECTION VIII: BUSINESS ASPECTS</b>	<b>643</b>
<b>Introduction</b>	643
<b>50 The Multinational Corporations: Cultural Challenges, the Legal/Regulatory Framework and the Medico-commercial Environment</b>	645
<i>R. Drucker and R. Graham Hughes</i>	
<b>51 Advertising and Marketing</b>	653
<i>Jonathan Belsey</i>	
<b>52 Middle East, India, China and the Far East: Pharmaceutical Medicine in the East</b>	665
<i>Gamal Hammad</i>	
<b>53 Financial Aspects of Clinical Trials</b>	689
<i>R.G. Hughes and N. Turner</i>	
<b>54 Outsourcing Clinical Drug Development Activities to Contract Research Organizations (CROs): Critical Success Factors</b>	701
<i>John R. Vogel</i>	
<b>55 The Impact of Managed Care on the US Pharmaceutical Industry</b>	725
<i>Robert J. Chaponis, Christine Hanson-Divers, and Marilyn J. Wells</i>	
<b>Appendix: Useful Internet Links</b>	<b>745</b>
<b>Index</b>	<b>749</b>